Market Research

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market - Global Size, Share, Trend Analysis, Opportunity and Forecast, 2019–2030, Segmented By Type of Infection (Hospital-acquired ABSSI, Community-acquired ABSSI); By Route of Administration (O

Best Price Guarantee Length Publisher Published Date SKU
from $4,850 400 Pages BlueWeave Consulting July, 2024 BLWC19215093
Best Price Guarantee
Price from $4,850
Length 400 Pages
Publisher BlueWeave Consulting
Published Date July, 2024
SKU BLWC19215093

Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market - Global Size, Share, Trend Analysis, Opportunity and Forecast, 2019–2030, Segmented By Type of Infection (Hospital-acquired ABSSI, Community-acquired ABSSI); By Route of Administration (Oral, Parenteral, Topical); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Region (North America, Europe, Asia Pacific (APAC), Latin America (LATAM), Middle East and Africa (MEA))


Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Size Zooming 2.4X at Stellar CAGR to Touch USD 23.5 Billion by 2030
Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is flourishing at a significant growth rate due to increasing ABSSSI incidence rates, antibiotic resistance, advancements in treatment options, and rising healthcare expenditure and awareness initiatives.

BlueWeave Consulting, a leading strategic consulting, and Market research firm, in its recent study, estimated Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market size by value at USD 9.65 billion in 2023. During the forecast period between 2024 and 2030, BlueWeave expects Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market size to expand at a CAGR of 10.55% reaching a value of USD 23.49 billion in 2030. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is growing at a significant rate due to increasing awareness and R&D activities by pharmaceutical and biopharmaceutical companies. Common bacteria causing these infections include Streptococcus pyogenes and Staphylococcus aureus, with anti-MRSA drugs being a crucial emerging concept. Pipeline development, R&D expenditure, and drug approvals are expected to drive the market. Key market players, such as Melinta Therapeutics, are also launching new products and activities, such as KIMYRSA, a lipoglycopeptide antibiotic. These factors are expected to drive the market during the forecast period.
Opportunity – Technological advancements in diagnostics and treatment
Recent innovations in diagnostic tools and treatment modalities are revolutionizing the landscape of Global Acute Bacterial Skin And Skin Structure Infections (ABSSSI) Market. Advanced imaging techniques and rapid diagnostic tests are enhancing early detection, leading to prompt interventions and improved patient outcomes. Moreover, the development of novel antibiotics and therapies tailored to antibiotic-resistant strains is addressing previously unmet medical needs. These technological strides are not only reducing hospital stays and healthcare costs but also expanding the market scope globally. As a result, Global ABSSSI Market is poised for substantial growth driven by continuous advancements in medical technology.
Impact of Escalating Geopolitical Tensions on Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market
Intensifying geopolitical tensions are causing significant disruptions in Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market. Disruptions in supply chains, particularly for antibiotics and medical supplies, hinder patient care and treatment efficacy. Political instability and economic sanctions can also hinder pharmaceutical manufacturing and distribution, leading to drug shortages and increased costs. Reduced international collaboration and strained diplomatic relations can stifle research and development efforts.
Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market
Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market – By Distribution Channel
Based on distribution channel, Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies segments. The hospital pharmacies segment dominates the Global ABSSSI Market due to their ability to manage complex infections effectively, provide timely access to necessary medications, and offer advanced healthcare infrastructure, particularly in hospital settings where immediate and intensive care is required.
Competitive Landscape
Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is fiercely competitive. Major companies in the market include Pfizer, Merck & Co., AbbVie, F. Hoffmann-La Roche Ltd, GlaxoSmithKline, Johnson & Johnson, Eli Lilly and Company, Novartis AG, Sanofi S.A., AstraZeneca PLC, Teva Pharmaceutical Industries Ltd, and Mylan N.V. These companies use various strategies, including increasing investments in their R&D activities, mergers and acquisitions, joint ventures, collaborations, licensing agreements, and new product and dose releases to further strengthen their position in Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market.


The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market and industry insights to help decision-makers make sound strategic decisions. Further, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.


1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Executive Summary
3. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Insights
3.1. Industry Value Chain Analysis
3.2. DROC Analysis
3.2.1. Growth Drivers
3.2.1.1. Rising Prevalence of Antibiotic Resistance
3.2.1.2. Aging Population
3.2.1.3. Increase in Invasive Medical Procedures
3.2.1.4. Growing Awareness of ABSSSI
3.2.2. Restraints
3.2.2.1. High Cost of Treatment
3.2.2.2. Limited Availability of Effective Antibiotics
3.2.3. Opportunities
3.2.3.1. Technological Advancements in Diagnostics and Treatment
3.2.3.2. Focus on Emerging Markets
3.2.4. Challenges
3.2.4.1. Improper Antibiotic Use and Self-Medication
3.2.4.2. Lack of Awareness and Hygiene Practices
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter’s Five Forces Analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market: Marketing Strategies
5. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market: Geographical Analysis
5.1. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, Geographical Analysis, 2023
5.2. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, Market Attractiveness Analysis, 2024–2030
6. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market Overview
6.1. Market Size & Forecast, 2019–2030
6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
6.2.1. By Type of Infection
6.2.1.1. Hospital-acquired ABSSI
6.2.1.2. Community-acquired ABSSI
6.2.2. By Route of Administration
6.2.2.1. Oral
6.2.2.2. ParentaL
6.2.2.3. Topical
6.2.3. By Distribution Channel
6.2.3.1. Hospital Pharmacies
6.2.3.2. Retail Pharmacies
6.2.3.3. Online Pharmacies
6.2.4. By Region
6.2.4.1. North America
6.2.4.2. Europe
6.2.4.3. Asia Pacific (APAC)
6.2.4.4. Latin America (LATAM)
6.2.4.5. Middle East and Africa (MEA)
7. North America Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market
7.1. Market Size & Forecast, 2019–2030
7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
7.2.1. By Type of Infection
7.2.2. By Route of Administration
7.2.3. By Distribution Channel
7.2.4. By Country
7.2.4.1. United States
7.2.4.1.1. By Type of Infection
7.2.4.1.2. By Route of Administration
7.2.4.1.3. By Distribution Channel
7.2.4.2. Canada
7.2.4.2.1. By Type of Infection
7.2.4.2.2. By Route of Administration
7.2.4.2.3. By Distribution Channel
8. Europe Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market
8.1. Market Size & Forecast, 2019–2030
8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
8.2.1. By Type of Infection
8.2.2. By Route of Administration
8.2.3. By Distribution Channel
8.2.4. By Country
8.2.4.1. Germany
8.2.4.1.1. By Type of Infection
8.2.4.1.2. By Route of Administration
8.2.4.1.3. By Distribution Channel
8.2.4.2. United Kingdom
8.2.4.2.1. By Type of Infection
8.2.4.2.2. By Route of Administration
8.2.4.2.3. By Distribution Channel
8.2.4.3. Italy
8.2.4.3.1. By Type of Infection
8.2.4.3.2. By Route of Administration
8.2.4.3.3. By Distribution Channel
8.2.4.4. France
8.2.4.4.1. By Type of Infection
8.2.4.4.2. By Route of Administration
8.2.4.4.3. By Distribution Channel
8.2.4.5. Spain
8.2.4.5.1. By Type of Infection
8.2.4.5.2. By Route of Administration
8.2.4.5.3. By Distribution Channel
8.2.4.6. Belgium
8.2.4.6.1. By Type of Infection
8.2.4.6.2. By Route of Administration
8.2.4.6.3. By Distribution Channel
8.2.4.7. Russia
8.2.4.7.1. By Type of Infection
8.2.4.7.2. By Route of Administration
8.2.4.7.3. By Distribution Channel
8.2.4.8. The Netherlands
8.2.4.8.1. By Type of Infection
8.2.4.8.2. By Route of Administration
8.2.4.8.3. By Distribution Channel
8.2.4.9. Rest of Europe
8.2.4.9.1. By Type of Infection
8.2.4.9.2. By Route of Administration
8.2.4.9.3. By Distribution Channel
9. Asia Pacific Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market
9.1. Market Size & Forecast, 2019–2030
9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
9.2.1. By Type of Infection
9.2.2. By Route of Administration
9.2.3. By Distribution Channel
9.2.4. By Country
9.2.4.1. China
9.2.4.1.1. By Type of Infection
9.2.4.1.2. By Route of Administration
9.2.4.1.3. By Distribution Channel
9.2.4.2. India
9.2.4.2.1. By Type of Infection
9.2.4.2.2. By Route of Administration
9.2.4.2.3. By Distribution Channel
9.2.4.3. Japan
9.2.4.3.1. By Type of Infection
9.2.4.3.2. By Route of Administration
9.2.4.3.3. By Distribution Channel
9.2.4.4. South Korea
9.2.4.4.1. By Type of Infection
9.2.4.4.2. By Route of Administration
9.2.4.4.3. By Distribution Channel
9.2.4.5. Australia & New Zealand
9.2.4.5.1. By Type of Infection
9.2.4.5.2. By Route of Administration
9.2.4.5.3. By Distribution Channel
9.2.4.6. Indonesia
9.2.4.6.1. By Type of Infection
9.2.4.6.2. By Route of Administration
9.2.4.6.3. By Distribution Channel
9.2.4.7. Malaysia
9.2.4.7.1. By Type of Infection
9.2.4.7.2. By Route of Administration
9.2.4.7.3. By Distribution Channel
9.2.4.8. Singapore
9.2.4.8.1. By Type of Infection
9.2.4.8.2. By Route of Administration
9.2.4.8.3. By Distribution Channel
9.2.4.9. Vietnam
9.2.4.9.1. By Type of Infection
9.2.4.9.2. By Route of Administration
9.2.4.9.3. By Distribution Channel
9.2.4.10. Rest of APAC
9.2.4.10.1. By Type of Infection
9.2.4.10.2. By Route of Administration
9.2.4.10.3. By Distribution Channel
10. Latin America Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market
10.1. Market Size & Forecast, 2019–2030
10.1.1. By Value (USD Million)
10.2. Market Share & Forecast
10.2.1. By Type of Infection
10.2.2. By Route of Administration
10.2.3. By Distribution Channel
10.2.4. By Country
10.2.4.1. Brazil
10.2.4.1.1. By Type of Infection
10.2.4.1.2. By Route of Administration
10.2.4.1.3. By Distribution Channel
10.2.4.2. Mexico
10.2.4.2.1. By Type of Infection
10.2.4.2.2. By Route of Administration
10.2.4.2.3. By Distribution Channel
10.2.4.3. Argentina
10.2.4.3.1. By Type of Infection
10.2.4.3.2. By Route of Administration
10.2.4.3.3. By Distribution Channel
10.2.4.4. Peru
10.2.4.4.1. By Type of Infection
10.2.4.4.2. By Route of Administration
10.2.4.4.3. By Distribution Channel
10.2.4.5. Rest of LATAM
10.2.4.5.1. By Type of Infection
10.2.4.5.2. By Route of Administration
10.2.4.5.3. By Distribution Channel
11. Middle East & Africa Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market
11.1. Market Size & Forecast, 2019–2030
11.1.1. By Value (USD Million)
11.2. Market Share & Forecast
11.2.1. By Type of Infection
11.2.2. By Route of Administration
11.2.3. By Distribution Channel
11.2.4. By Country
11.2.4.1. Saudi Arabia
11.2.4.1.1. By Type of Infection
11.2.4.1.2. By Route of Administration
11.2.4.1.3. By Distribution Channel
11.2.4.2. UAE
11.2.4.2.1. By Type of Infection
11.2.4.2.2. By Route of Administration
11.2.4.2.3. By Distribution Channel
11.2.4.3. Qatar
11.2.4.3.1. By Type of Infection
11.2.4.3.2. By Route of Administration
11.2.4.3.3. By Distribution Channel
11.2.4.4. Kuwait
11.2.4.4.1. By Type of Infection
11.2.4.4.2. By Route of Administration
11.2.4.4.3. By Distribution Channel
11.2.4.5. South Africa
11.2.4.5.1. By Type of Infection
11.2.4.5.2. By Route of Administration
11.2.4.5.3. By Distribution Channel
11.2.4.6. Nigeria
11.2.4.6.1. By Type of Infection
11.2.4.6.2. By Route of Administration
11.2.4.6.3. By Distribution Channel
11.2.4.7. Algeria
11.2.4.7.1. By Type of Infection
11.2.4.7.2. By Route of Administration
11.2.4.7.3. By Distribution Channel
11.2.4.8. Rest of MEA
11.2.4.8.1. By Type of Infection
11.2.4.8.2. By Route of Administration
11.2.4.8.3. By Distribution Channel
12. Competitive Landscape
12.1. List of Key Players and Their Offerings
12.2. Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Company Market Share Analysis, 2023
12.3. Competitive Benchmarking, By Operating Parameters
12.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
13. Impact of Escalating Geopolitical Tensions on Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market
14. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
14.1. Pfizer
14.2. Merck & Co.
14.3. AbbVie
14.4. F. Hoffmann-La Roche Ltd
14.5. GlaxoSmithKline
14.6. Johnson & Johnson
14.7. Eli Lilly and Company
14.8. Novartis AG
14.9. Sanofi S.A.
14.10. AstraZeneca PLC
14.11. Teva Pharmaceutical Industries Ltd
14.12. Mylan N.V.
14.13. Other Prominent Players
15. Key Strategic Recommendations
16. Research Methodology
16.1. Qualitative Research
16.1.1. Primary & Secondary Research
16.2. Quantitative Research
16.3. Market Breakdown & Data Triangulation
16.3.1. Secondary Research
16.3.2. Primary Research
16.4. Breakdown of Primary Research Respondents, By Region
16.5. Assumptions & Limitations
*Financial information of non-listed companies can be provided as per availability.
**The segmentation and the companies are subject to modifications based on in-depth secondary research for the final deliverable

$4,850
$5,750
$8,150

Research Assistance

US: 800.298.5699
Int'l: +1.240.747.3093
Live help
Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Other tasks

Cookie Settings